Patent details

Basic Information

Publication number:

EP3493830

PCT Application Number:

US2017045573

Type:

European Patent Granted for LU

Legal Status:

Unitary Effect Registered

Application number:

EP177542404

PCT Publication Number:

WO2018027169

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

USE OF ADAMTS13 FOR TREATING, AMELIORATING AND/OR PREVENTING VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE, ACUTE LUNG INJURY AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME

French Title of Invention:

UTILISATION D'ADAMTS13 EN VUE DE TRAITER, DE FAIRE RÉGRESSER ET/OU DE PRÉVENIR UNE CRISE VASO-OCCLUSIVE LORS D'UNE DRÉPANOCYTOSE, UNE LÉSION PULMONAIRE AIGUË ET/OU UN SYNDROME DE DÉTRESSE RESPIRATOIRE AIGUË

German Title of Invention:

VERWENDUNG VON ADAMTS13 ZUR BEHANDLUNG, LINDERUNG UND/ODER PRÄVENTION EINER VASO-OKKLUSIVEN KRISE BEI SICHELZELLANÄMIE, AKUTER LUNGENLÄSION UND/ODER AKUTEM ATEMSTRESSSYNDROM

SPC Number:

Unitary Effect

Unitary Effect Requested:

Yes

Unitary Effect Request Filing Date:

31/12/2025

Link to UPP Register:

European Patent Register

Unitary Effect Request Withdrawal Date:

Unitary Effect Status:

Unitary Effect Registered

Unitary Effect Acceptance Decision Date:

12/01/2026

Unitary Effect Rejection Decision Date:

Unitary Effect Date:

03/12/2025

Unitary Effect Registration Date:

12/01/2026

Unitary Effect Re-establishment of rights Filing Date:

Unitary Effect Re-establishment of rights EPO Decision :

Unitary Effect Re-establishment of rights EPO Decision Date:

Explanatory Text UE:

Safety Net Request Date:

Safety Net Decision Date:

Safety Net Decision Outcome:

SPC Number:

Dates

Filing date:

04/08/2017

Grant date:

03/12/2025

EP Publication Date:

12/06/2019

PCT Publication Date:

08/02/2018

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

03/12/2025

EP B1 Publication Date:

03/12/2025

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

04/08/2037

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

26/11/2025

 

 

Name:

Takeda Pharmaceutical Company Limited

Address:

1-1, Doshomachi 4-chome Chuo-ku, Osaka-shi, Osaka, Japan (JP)

Inventor

1

Name:

GOLDSTEIN, Brahm

Address:

United States (US)

2

Name:

TURECEK, Marietta

Address:

Austria (AT)

3

Name:

SCHEIFLINGER, Friedrich

Address:

Austria (AT)

4

Name:

MAJER, Bernhard

Address:

Austria (AT)

5

Name:

ROSSATO, Paolo

Address:

Austria (AT)

6

Name:

EWENSTEIN, Bruce

Address:

United States (US)

Priority

Priority Number:

201662371030 P

Priority Date:

04/08/2016

Priority Country:

United States (US)

Classification

IPC classification:

A61K 38/48; A61P 7/02; A61P 9/00; A61P 11/00; A61P 25/04;

Publication

European Patent Bulletin

1

Issue number:

202549

Publication date:

03/12/2025

Description:

Grant (B1)

2

Issue number:

202606

Publication date:

04/02/2026

Description:

Unitary Effect Request Receipt

3

Issue number:

202607

Publication date:

11/02/2026

Description:

Unitary Effect Request Acceptance

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages